NO-SCA FORTE

Active material: Drotaverine
When ATH: A03AD02
CCF: Myotropic antispasmodic
ICD-10 codes (testimony): G45, I73.9, K25, K26, K29, K31.3, K52, K81.0, K81.1, K82.8, K91.5, N20, N21, N23, N94.4, N94.5, O62, Z29.8
When CSF: 01.14.05
Manufacturer: CHINOIN Pharmaceutical and Chemical Works Co. Ltd. (Hungary)

Pharmaceutical form, composition and packaging

◊Pills convex, oblong, yellow with a greenish or orange tint, marking on one side “NOSpA”, another – risk.

Excipients: magnesium stearate, talc, povidone, corn starch, lactose.

10 PC. – blisters (2) – packs cardboard.

Pharmacological action

Myotropic antispasmodic. On chemical structure and pharmacological properties similar to papaverine, but has a strong and long-acting. Reduce intake of calcium in the smooth muscle cells (It inhibits phosphodiesterase, It leads to the accumulation of intracellular cAMP). It reduces the tone of smooth muscles of internal organs and intestinal peristalsis, dilates blood vessels.

No effect on the autonomic nervous system, It does not penetrate the CNS.

Have a direct effect on the smooth muscles of the drug can be used as an antispasmodic in cases, when contraindicated drugs from the group of m-holinoblokatorov (zakrыtougolynaya glaucoma, prostate adenoma).

Pharmacokinetics

Absorption

If ingestion drotaverine rapidly absorbed from the gastrointestinal tract, period poluabsorbtsii – 12 m. Bioavailability – about 100%. C_max in serum obtained through 2 no.

Distribution

Plasma protein binding – 95-98%. Evenly distributed in the tissues, It penetrates into the smooth muscle cells. Drotaverine does not penetrate the blood-brain barrier.

Deduction

Excreted in the urine, less – the bile.

Testimony

- Prevention and treatment of functional disorders and pain, induced smooth muscle spasm (incl. in chronic gastroduodenitis, chronic cholecystitis, cholelithiasis, postcholecystectomy syndrome, gastric ulcer and duodenal ulcer, spasms of the pyloric and gastric cardia, spasticheskom cars, urolithiasis);

- Algomenorrhea;

- To weaken uterine contractions and cervical spasm relief in labor;

- Spasms of peripheral arterial disease, cerebrovascular;

- Prevention of smooth muscle spasm during the instrumental studies.

Dosage regimen

The drug is prescribed inside adult by 40-80 mg (1/2-1 tab.) 2-3 times / day; children aged 6 to 12 years – by 20 mg (1/4 tab.) 1-2 times / day.

Side effect

Maybe: dizziness, palpitations, decrease in blood pressure, feeling the heat, increased sweating, allergic skin reactions.

Contraindications

- Severe hepatic impairment;

- Expressed by the human kidney;

- Severe heart failure;

— AV-blockade II and III degrees;

- Cardiogenic shock;

- Hypotension;

- Hypersensitivity to the drug.

FROM caution prescribe the drug to patients with severe coronary atherosclerosis, BPH, glaukomoj, Pregnancy and lactation.

Pregnancy and lactation

Precautions should be prescribed the drug during pregnancy. During the period of lactation (breast-feeding) appoint drotaverine not recommended due to the lack of clinical data.

Cautions

–

Overdose

In high doses, it violates AV-conduction, reduces the excitability of cardiac muscle, can cause heart failure and paralysis of the respiratory center.

Drug Interactions

At simultaneous application But-spa^® Forte could weaken the antiparkinsonian effect of levodopa.

At simultaneous application But-spa^® Fort enhances the effect of papaverine, bendazol and other antispasmodics (incl. Mr. holinoblokatorov).

In an application with Nospanum^® Fort tricyclic antidepressants, quinidine and procainamide enhanced hypotensive effect.

At simultaneous application But-spa^® Fort reduces the activity of morphine spasmogenic.

With simultaneous use of phenobarbital increases the severity of antispasmodic action drotaverine.

Conditions of supply of pharmacies

The drug is resolved to application as an agent Valium holidays.

Conditions and terms

List B. The drug should be stored out of reach of children at temperature from 15 ° to 25 ° C. Shelf life – 5 years.